celecoxib has been researched along with Ewing Sarcoma in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previously, we reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, prevented lung metastases but did not affect tumor growth in a model of Ewing sarcoma." | 7.78 | Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012) |
| "Previously, we reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, prevented lung metastases but did not affect tumor growth in a model of Ewing sarcoma." | 3.78 | Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012) |
| "Celecoxib prevents lung metastasis in a murine model of Ewing sarcoma with no effect on tumor size or neovascularization." | 3.77 | Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. ( Edelman, M; Gendy, AS; Glick, RD; Lipskar, A; Soffer, SZ; Steinberg, BM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pramanik, R | 1 |
| Agarwala, S | 1 |
| Gupta, YK | 1 |
| Thulkar, S | 1 |
| Vishnubhatla, S | 1 |
| Batra, A | 1 |
| Dhawan, D | 1 |
| Bakhshi, S | 1 |
| Behr, CA | 1 |
| Hesketh, AJ | 1 |
| Barlow, M | 2 |
| Glick, RD | 3 |
| Symons, M | 1 |
| Steinberg, BM | 3 |
| Soffer, SZ | 3 |
| Gendy, AS | 1 |
| Lipskar, A | 1 |
| Edelman, M | 2 |
| Felgenhauer, JL | 1 |
| Nieder, ML | 1 |
| Krailo, MD | 1 |
| Bernstein, ML | 1 |
| Henry, DW | 1 |
| Malkin, D | 1 |
| Baruchel, S | 1 |
| Chuba, PJ | 1 |
| Sailer, SL | 1 |
| Brown, K | 1 |
| Ranganathan, S | 1 |
| Marina, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low Dose Chemotherapy (Metronomic Therapy) Versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies: a Double Blind Placebo Controlled Randomized Study[NCT01858571] | Phase 3 | 108 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors[NCT00061893] | Phase 2 | 38 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00061893)
Timeframe: 24 months after start of protocol therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Combination Chemotherapy | 35 |
An incidence of severe toxicity is defined to be the occurrence of grade 3 or higher infection or grade 3 or higher sensory neuropathy during cycles 1-2 of protocol therapy. If 12 or more patients experience grade 3 or higher infection or five or more patients experience grade 3 or higher sensory neuropathy during cycles 1-2 of protocol therapy, the regimen will be flagged as being associated with an excessive rate of severe toxicity. (NCT00061893)
Timeframe: The first two cycles (6 weeks) of protocol chemotherapy
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3 or Higher Infection | Grade 3 or Higher Sensory Neuropathy | |
| Combination Chemotherapy | 1 | 1 |
2 trials available for celecoxib and Ewing Sarcoma
| Article | Year |
|---|---|
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy P | 2017 |
A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chil | 2013 |
3 other studies available for celecoxib and Ewing Sarcoma
| Article | Year |
|---|---|
Celecoxib inhibits Ewing sarcoma cell migration via actin modulation.
Topics: Actin Cytoskeleton; Actins; beta Catenin; Caco-2 Cells; Celecoxib; Cell Movement; Cyclooxygenase 2 I | 2015 |
Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 In | 2011 |
Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.
Topics: Basement Membrane; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Cyc | 2012 |